Enanta Pharmaceuticals (ENTA) Competitors $6.56 -0.42 (-6.02%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.56 0.00 (-0.08%) As of 07/11/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPBShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Its Competitors Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma Autolus Therapeutics ChromaDex Cidara Therapeutics Arbutus Biopharma Evolus Upstream Bio Enanta Pharmaceuticals (NASDAQ:ENTA) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Do analysts recommend ENTA or STOK? Enanta Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 174.39%. Stoke Therapeutics has a consensus price target of $24.75, suggesting a potential upside of 108.68%. Given Enanta Pharmaceuticals' higher possible upside, equities research analysts clearly believe Enanta Pharmaceuticals is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Does the media favor ENTA or STOK? In the previous week, Stoke Therapeutics had 17 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 18 mentions for Stoke Therapeutics and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.87 beat Stoke Therapeutics' score of 0.04 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Enanta Pharmaceuticals Very Positive Stoke Therapeutics Neutral Which has stronger earnings and valuation, ENTA or STOK? Stoke Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$64.46M2.18-$116.04M-$4.54-1.44Stoke Therapeutics$36.56M17.71-$88.98M$0.7915.01 Which has more volatility and risk, ENTA or STOK? Enanta Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Is ENTA or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Enanta Pharmaceuticals' net margin of -149.57%. Stoke Therapeutics' return on equity of 19.08% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-149.57% -79.83% -26.65% Stoke Therapeutics 26.33%19.08%15.72% Do institutionals and insiders hold more shares of ENTA or STOK? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryStoke Therapeutics beats Enanta Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.23M$2.50B$5.60B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-1.449.4227.9620.25Price / Sales2.18723.99429.2099.14Price / CashN/A165.3637.4658.16Price / Book1.084.608.045.49Net Income-$116.04M$31.26M$3.18B$250.27M7 Day Performance-16.86%4.80%3.63%4.75%1 Month Performance-11.47%5.42%4.04%7.64%1 Year Performance-59.00%-4.36%29.56%16.34% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.9218 of 5 stars$6.56-6.0%$18.00+174.4%-56.2%$140.23M$64.46M-1.44160Positive NewsSTOKStoke Therapeutics4.1407 of 5 stars$11.35-2.4%$23.20+104.4%-15.5%$634.96M$36.56M14.37100Trending NewsSANASana Biotechnology3.13 of 5 stars$2.73-2.8%$8.60+215.0%-26.1%$633.59MN/A-3.10380MRVIMaravai LifeSciences3.6135 of 5 stars$2.41-2.4%$6.64+175.5%-68.3%$629.01M$259.18M-2.11610Options VolumeGap DownURGNUrogen Pharma4.5328 of 5 stars$13.70+1.6%$32.86+139.8%-15.7%$621.99M$90.40M-4.31200Analyst ForecastAUTLAutolus Therapeutics2.8695 of 5 stars$2.28-1.3%$9.32+308.8%-40.5%$614.79M$10.12M-2.59330CDXCChromaDex3.1362 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120CDTXCidara Therapeutics4.1398 of 5 stars$48.71-1.5%$57.14+17.3%+348.8%$603.74M$1.27M-1.6590Positive NewsAnalyst ForecastGap UpHigh Trading VolumeABUSArbutus Biopharma2.2962 of 5 stars$3.09-1.3%$5.50+78.0%-9.7%$599.48M$6.17M-7.5490Positive NewsEOLSEvolus3.9207 of 5 stars$9.21+0.8%$23.75+157.9%-18.8%$589.31M$266.27M-10.35170UPBUpstream Bio1.9558 of 5 stars$10.98+0.5%$56.50+414.6%N/A$587.97M$2.37M0.0038 Related Companies and Tools Related Companies STOK Competitors SANA Competitors MRVI Competitors URGN Competitors AUTL Competitors CDXC Competitors CDTX Competitors ABUS Competitors EOLS Competitors UPB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
